Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.56 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307183 | 0.85 | ROCK2 (0.68) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL306946 | 0.84 | ROCK2 (0.68) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL306732 | 0.82 | ROCK2 (0.72) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL307311 | 0.77 | ROCK2 (0.73) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL4437493 | 0.75 | ROCK2 (0.70) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL305141 | 0.73 | ROCK2 (0.78) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL3609921 | 0.73 | ROCK2 (0.78) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL305398 | 0.73 | ROCK2 (0.78) | ROCK2CYP3A4ROCK1CYP2C9SMN1; SMN2 | |
| SCHEMBL307174 | 0.73 | ROCK2 (0.64) | ROCK2PKN2CYP3A4ROCK1CYP2C9 | |
| SCHEMBL10159707 | 0.73 | ROCK2 (0.64) | ROCK2PKN2CYP3A4ROCK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | claimed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | claimed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | ROCK2 4/4885PKN2 332/4885CYP3A4 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.